On November 14th 2017, the Court affirmed the March 31st 2017 ruling by the Patent Trial and Appeal Board of the United States Patent and Trademark Office,
invalidating all patent
claims in United Therapeutics»
key patent covering its products Remodulin, Tyvaso, and Orenitram.